Metastasis involves the interaction of the tumor, immune and endothelial cells. Cell death proteins, such as inhibitors of apoptosis proteins (IAPs), are critical players in survival, inflammation and permeability. Whether the use of Smac mimetics, which target cIAP1/2 for degradation would affect metastasis is unknown. We show Smac mimetics reduced metastasis due to the loss of cIAP1 but not cIAP2 in experimental metastasis models. The endothelial compartment rather than the immune cells was responsible for reduction of extravasation upon loss of cIAP1. Loss of cIAP1 in primary endothelial cells did not lead to cell death but resulted in an unresponsive endothelium barrier to permeability factors causing a reduction in tumor cell extravasation. Unexpectedly, the co-loss of TNFR1 and cIAP1 restored the tumor load. We were surprised to find lymphotoxin alpha (LTA), and not TNF, secreted by the tumor cells was critical for the extravasation. Using TCGA data, we found high levels of LTA mRNA expression correlated with decreased survival in kidney carcinoma and associated with advance disease stage. Our data suggest that Smac mimetics, targeting cIAP1/2, may reduce metastasis to the lung through a LTA/TNFR mechanism by altering the endothelial barrier and inhibiting the ability of tumor cells to extravasate.
Introduction
Elevated levels of cIAPs (cIAP1/2), in part due to genomic amplification, have been reported in a variety of human cancers such as hepatocellular carcinoma (1) , lung cancer (2) and esophageal squamous cell carcinoma (3) . In cervical squamous cell carcinoma, elevated levels of cIAP1 are correlated with chemoresistance to radiotherapy(4) and in colorectal and bladder cancer elevated levels of cIAPs are correlated with advanced stages of tumors and poor survival (3, 4) .
Because of the role of IAPs to inhibit cell death, pharmaceutical companies developed synthetic compounds to mimic the naturally inhibitor of IAPs, Smac/DIABLO (5, 6) .
The release of Smac from the mitochondria results in autoubiquitination and degradation of cIAP1 and cIAP2 by binding to their BIR3 domain (5, 6) and inhibition of XIAP and caspases through the binding of the BIR2 and BIR3 domain of XIAP (7) . Likewise, Smac mimetics cause the proteasomal degradation of cIAP1/2 and activation of the alternative NF-κB pathway. NF-κB drives TNF production and in the absence of cIAP1, TNFR1 activation leads to the formation of complex II and subsequent cell death (8) (9) (10) (11) . TNFR2 activation in the absence of IAPs also induces cell death through a TNF/TNFR1 mechanism (12, 13) .
Numerous studies have implicated Smac mimetics in modifying the immune system to cause tumor cell death and reduce tumor burden alone or in combination with known immune modulators (14) (15) (16) (17) (18) . Moreover, in a B16-F10 subcutaneous tumor model, delivery of Smac mimetic in the tumor site disrupted neo-angiogenesis due to cell death which was rescued by the co-loss of TNFR1/2 (19) . These results suggest that IAP inhibitors may be used to target the primary tumor, although past clinical trials with IAP inhibitors as single agents have shown poor efficacy.
The majority of patients however, die not due to the primary tumor but because of metastasis. For tumor cells to metastasize, the cells must enter the blood stream, survive within the circulatory system and then extravasate at a secondary site (20) . Developmental studies show that the loss of cIAP1/2 results in hemorrhage and loss of endothelial cell integrity (21, 22) . Tumor cell-induced endothelial cell death has been implicated as a mode of metastasis(23). Alternatively, loss of cell death proteins in endothelial cells reduced permeability but not viability suggesting a non-cell death function for cell death proteins in endothelial cells (24, 25) . Whether Smac mimetics would compromise endothelial cell integrity past development and enhance metastasis is unknown.
Here, we show that the loss of cIAP1 but not cIAP2 in the endothelium obstructs tumor cells extravasation into the lung. Surprisingly, there is no evidence of cell death in this process and the results can be re-capitulated using Smac mimetics (Birinapant). Combined loss of TNFR1 and cIAP1 reverses this phenotype, allowing tumor cells to extravasate into the lung. Our data show that LTA secreted from the tumor cell requires cIAP1 expression in the endothelium to induce tumor cell extravasation. These results suggest that application of Smac mimetics in the clinics might not only contribute to tumor killing by activating the immune system but also prevent tumor metastasis of individual cancer types.
Results and Discussion

Smac mimetics decreased tumor load in the lung through reduction of cIAP1 but not cIAP2
To determine if Smac mimetics would alter metastasis, we chose a model that allowed us to focus on the latter part of metastasis. Tumor cells injected intravenously, circulate to the lung, extravasate and form tumor nodules. Birinapant, a Smac mimetic in Phase II clinical trials, was used to target cIAP1/2. Injection of Birinapant led to cIAP1 loss within 1 hour as shown in total lung homogenates and remained reduced up to 48 hours ( Figure 1A) .
Interestingly, treatment with Birinapant (72 and 24 hours prior to injection of B16-F10 melanoma cells) resulted in a significant reduction in lung tumor load at day 13 post tumor challenge ( Figure 1B ). Injection of Birinapant 6 hours prior to injection of tumor cells, however, did not affect tumor load in the lung (Supplemental Figure 1A) . Although Smac mimetics have been shown to cause tumor cell death in vivo because of exogenous TNF production from innate immune cells (14, 16) , B16-F10 cells were resistant to TNF-induced cell death even in the presence of Smac mimetics (Supplemental Figure 1B) .
To identify whether the loss of cIAP1 or cIAP2 played a dominant role in reducing the number of tumor nodules, we utilized ciap1 -/-ciap2 frt/frt (ciap1 -/-) and ciap1 fl/fl ciap2 -/-(ciap2 -/-) mice to mimic the effect of Smac mimetics on the host alone. Approximately 50% fewer tumor nodules were identified in the lungs of ciap1 -/compared to ciap1 fl/fl ciap2 frt/frt (ciap1 fl/fl ) mice, whereas ciap1 fl/mice showed an intermediate phenotype ( Figure 1C ). However, the tumor load in ciap2 -/mice was similar to widltype mice, suggesting the loss of cIAP1 was the reason for the reduction in tumor nodule numbers. To assess the tumor load in an unbiased manner, B16-F10 luciferase cells were utilized and a significant reduction in bioluminescence intensity was observed in ciap1 -/mice, correlating with the tumor nodule counts ( Figure 1D ). Because a previous study using the B16-F10 tumor model showed reduction in subcutaneous tumor growth upon Smac mimetic treatment (Compound A, targeting cIAP1/2 and XIAP)(19) and to ensure tumor cells were not immunologically rejected in ciap1 -/mice, we injected B16-F10 tumor cells subcutaneously. No difference in tumor growth kinetics among ciap1 fl/fl , ciap1 -/or ciap2 -/mice was observed ( Figure 1E ). To determine if tumor nodules formed in the lung by other syngeneic tumor lines may be affected by cIAP1 loss in the tumor microenvironment, MC-38 GFP colon carcinoma cells or Lewis lung carcinoma cells (LLC) were injected intravenously and 21 days post injection, the number of tumor nodules were counted. We observed a 75% reduction in MC-38 GFP tumor nodules in the lungs of ciap1 -/compared to wildtype mice, while no reduction in tumor nodules was seen when LLC cells were injected ( Figure 1F and Supplemental Figure 1C ). These data suggest the ability of Smac mimetics to reduce the metastatic potential of individual cancer types to the lung by targeting cIAP1 for degradation in the host.
Loss of cIAP1 in the radio-resistant but not the hematopoietic compartment causes lung tumor load decrease
The extravasation process during metastasis is aided by immune and stroma cells(26, 27). Therefore, we assessed innate immune cell infiltrates in the lung at different time points post tumor cell injection. Two important populations aiding tumor cell extravasation, the inflammatory monocytes/macrophages (Ly6C + ) and neutrophils (Ly6G + ), were similarly recruited to the lung at 2h upon tumor challenge in both wildtype and ciap1 -/mice. Other populations of the innate and adaptive immunity were assessed showing no major changes in kinetics, except from CD8 + T cells at the naïve stage. (Figure 2A , Supplemental Figure   2A ). Likewise, changes in extracellular remodeling factors, consisting of matrix metalloproteinase (MMP)-related factors, adhesion molecules and cytokines/chemokines were comparable between ciap1 -/and wildtype mice. Interestingly, MMP-12 (macrophage metalloelastase) has been shown to suppress lung metastases growth(28). In agreement, MMP-12 was detected in high amounts in the lung of ciap1 -/mice even in the unchallenged state ( Figure 2B and Supplemental Figure 2B -2D). Taken together, the recruitment of immune cells at the extravasation site and re-modelling of the extracellular matrix is not compromised upon loss of cIAP1, suggesting the immune system is a redundant factor influencing tumor metastasis in the absence of cIAP1.
To confirm that loss of cIAP1 in the immune system does not interfere with tumor metastasis, we crossed ciap1 fl/fl ciap2 frt/frt with Vav-cre mice to deplete cIAP1 specifically in the hematopoietic system (ciap1 vav ). cIAP1 deletion was confirmed by protein detection in spleen and thymus ( Figure 2C ). B16-F10 melanoma cells were injected intravenously and the results showed that there was no reduction in the number of tumor colonies formed in the lungs of ciap1 vav mice compared to ciap1 fl/fl mice ( Figure 2D ).
To determine whether the loss of cIAP1 in the stromal compartment conferred reduction of lung tumor colonization, ciap1 fl/fl and ciap1 -/mice were reconstituted with CD45.1 wildtype bone marrow. We observed a significant reduction of tumor nodules formed in the lungs of cIAP1 deficient recipients ( Figure 2E ). Together, the data suggest that cIAP1 is not essential for the recruitment of immune cells early upon tumor challenge and that the immune system deficient in cIAP1 at steady state does not influence the ability of tumor cells to home to the lung. Moreover, cIAP1 in the radio-resistant compartment promoted lung colonization.
The ciap1 -/endothelium forms a stronger barrier against B16-F10 cell extravasation
To check whether the endothelium is the critical compartment in vivo for the reduction in the number of tumor colonies in the lungs of ciap1 -/mice, we crossed ciap1 fl/fl with tamoxifen inducible VE-cadherin-cre::ER mice (ciap1 VEC ). Here, ciap1 VEC mice showed reduced tumor colony numbers in the lung by approximately 50%, similar to complete ciap1 -/mice ( Figure   3A ), supporting the role of endothelium as the key player in our model. In the absence of cIAP1, cIAP2 up-regulation has been reported(29). However, combinatorial loss of cIAP1 and cIAP2 in the endothelium (ciap1 VEC ciap2 -/mice) displayed a similar reduction in tumor load compared to ciap1 VEC ciap2 frt/frt mice, suggesting potential up-regulation of cIAP2 did not prevent tumor cell lung colonization. The efficiency of knocking out ciap1 in the lung endothelium was confirmed by qPCR using primary isolated endothelial (CD31 + ) cells (75% reduction) ( Figure 3B ). Our previous data suggested that tumor growth is not hindered in ciap1 -/mice. Consequently, we focused on addressing whether tumor cells can transmigrate through the endothelial layer utilizing transmigration assays. The loss of cIAP1 in endothelial cells effectively reduced the number of transmigrating B16-F10 cells by 60% ( Figure 3C ). 
LTA but not TNF induces tumor cell extravasation via the TNFR1/cIAP1 axis
Since cIAP1 is well known to act downstream of the TNF/TNFRs pathway and TNF is a known cytokine involved in permeability, we examined whether TNF and TNFRs levels are influenced upon tumor challenge in the absence of cIAP1. Surprisingly, increasing levels of TNF could be detected in whole lung homogenates by luminex multiple assay 2h and 6h post tumor challenge, suggesting that TNF might be important for the extravasation of the tumor cells. While the levels of TNFR1 did not change, the levels of TNFR2 increased after tumor challenge ( Figure 4A ). Other angiogenic/permeability factors, such FGFb, did not show any fluctuation (Supplemental Figure 5 ).
To assess the involvement of TNFRs upstream of cIAP1 in tumor extravasation we analyzed the number of tumor colonies formed in the lungs of tnfr1 -/-, tnfr2 -/-, tnfr1 -/-ciap1 -/and tnfr2 -/-ciap1 -/mice. Loss of TNFR1 did not affect tumor colonies in the lung, while the loss of TNFR2 displayed an increased number of tumor nodules. Interestingly, tnfr1 -/-ciap1 -/had similar numbers of tumor nodules in the lung compared to wildtype mice, whereas tnfr2 -/-ciap1 -/mice mirrored the ciap1 -/phenotype ( Figure 4B ). Bone marrow chimera experiments further supported the combinatorial loss of TNFR1 and cIAP1 in the radio-resistant compartment was the cause for the restoration of the tumor load ( Figure 4C ). While TNFR1 has been identified as an important factor to induce endothelial permeability in vitro and in vivo, antibody blockade of TNFR2 hindered TNF-induced permeability in liver vessels, suggesting that TNFR2 can also contribute to the regulation of TNF-induced permeability in vivo(31). Together, these results suggest TNFR2 can compensate for the loss of TNFR1 even in the absence of cIAP1. Tnfr2 -/mice showed a higher number of tumor nodules in the lung, potentially because cIAP1 levels remain constant, supporting enhanced extravasation of tumor cells upon TNFR1 stimulation.
TNF and LTA are the known ligands for TNFR1 and TNFR2. We found the tumor load in tnf -/mice was comparable to wildtype mice and injection of anti-TNF into the mice did not prevent tumor cells from extravasating and forming tumor nodules in the lung ( Figure   4D and 4E). We then knocked out TNF or LTA in B16-F10 cells using CRISPR. Polyclonal populations selected by drug resistance were sequenced for genetic loss (Supplemental Figure 6A and 6B). Similar to our previous data, loss of TNF in B16-F10 cells did not affect tumor cell nodules in the lung but the loss of LTA caused a significant decrease in the tumor load ( Figure 4F ). These results suggest a mechanism in which B16-F10 tumor cell extravasation is mediated by the release of LTA and the subsequent activation of TNFRs.
To determine whether high expression of LTA and metastasis are associated, we The complexity of understanding the metastatic cascade lies in the numerous interactions and cell types that are involved in this process. By focusing on the last stages of metastasis we were able to identify a novel role of Smac mimetics against tumor extravasation. This particularly pertains to tumor types that metastasize to the lung. In agreement, Smac mimetics (JP1584) in combination with TRAIL antagonism had been used in an orthotopic syngeneic rat model of hepatic cholangiocarcinoma leading to a reduction in extrahepatic metastasis(33). Therefore, the promise of Smac mimetics as therapeutic agents might lie not only on targeting primary tumors but also being used as metastasis-reducing compounds in certain tumor types.
Materials and Methods
Animal work. Animals were maintained in specific pathogen free (SPF) and optimized A) Analysis of lung immune cell infiltrates following B16-F10 tumor challenge by flow cytometry. Inflammatory monocytes (CD11b high MHCII -SiglecF -Ly6G -Ly6C high ), patrolling monocytes (CD11b high MHCII -SiglecF -Ly6G -Ly6C low ), neutrophils (CD11b + Ly6G + ), natural killer (NK) cells (CD3 -NK1.1 + ), CD103 + DCs (CD11b int CD11c + CD24 + CD103 + ) and CD11b + DCs (CD11b high MHCII + CD24 + ) were pre-gated on singlets, live and CD45 + cells (n = 2 experiments, 6 mice/group). B) Levels of matrix metalloproteinase-related factors assessed using multiplex analysis assay of total lung lysates (n = 2 experiments, 6 mice/group). C) Spleen and thymus, composed mainly by blood cells, from ciap1 vav mice were analysed by western blotting to evaluate the levels of cIAP1. Representative immunoblot of n = 3 mice per group. D) Percentage of superficial B16-F10 tumor nodules normalized to the average of the wildtype control. Tumor cells were injected i.v. and nodules formed in the lung were counted 13 days later (n = >3 experiments). E) Percentage of superficial B16-F10 tumor nodules normalized to the average of the wildtype recipient control. Tumor cells were injected i.v. and nodules formed in the lung were counted 12 days later (n = 3 experiments). Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, ns = not significant. A) Levels of TNF and TNFRs assessed using multiplex analysis assay of total lung lysates (n = 2 experiments, 6 mice/group). B-E) Percentage of superficial B16-F10 tumor nodules normalized to the average of the respective controls. Tumor cells were injected i.v. into wt and transgenic mice (B, D), bone marrow chimeras (C) or antibody pre-treated wildtype mice (E), and nodules formed in the lung were counted 12 (C) or 13 days later (B, D-E). Data shown are pooled from n ≥ 3 (B), 3 (C), 2 (D), 1 (E) experiments. F) Percentage of superficial B16-F10 tumor nodules normalized to the average of the respective control. LentiCRISPR-engineered B16-F10 cells against tnf, lta and control (empty vector) were injected i.v. into wt mice and nodules formed in the lung were counted 12 days later (n = 3 experiments). G) Survival curve of high (>85th percentile) versus low (<15th percentile) LTA mRNA expression in kidney renal clear cell carcinoma from TCGA data and distribution of high versus low expression of LTA by disease stage. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001, ns = not significant. 2-way ANOVA with Bonferroni's test (A), 1-way ANOVA with Dunnett's test (B, C, F), two-tailed unpaired t-test (D, E). 
